CN106360708A - Pollen pini and lucid ganoderma granule for protective chemical liver damage and preparation method thereof - Google Patents
Pollen pini and lucid ganoderma granule for protective chemical liver damage and preparation method thereof Download PDFInfo
- Publication number
- CN106360708A CN106360708A CN201610729498.4A CN201610729498A CN106360708A CN 106360708 A CN106360708 A CN 106360708A CN 201610729498 A CN201610729498 A CN 201610729498A CN 106360708 A CN106360708 A CN 106360708A
- Authority
- CN
- China
- Prior art keywords
- pollen pini
- ganoderma
- dextrin
- parts
- granule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000222336 Ganoderma Species 0.000 title claims abstract description 60
- 239000000126 substance Substances 0.000 title claims abstract description 28
- 239000008187 granular material Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 206010067125 Liver injury Diseases 0.000 title abstract description 15
- 231100000234 hepatic damage Toxicity 0.000 title abstract 3
- 230000008818 liver damage Effects 0.000 title abstract 3
- 230000001681 protective effect Effects 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 claims abstract description 24
- 239000004375 Dextrin Substances 0.000 claims abstract description 22
- 229920001353 Dextrin Polymers 0.000 claims abstract description 22
- 235000019425 dextrin Nutrition 0.000 claims abstract description 22
- 239000007779 soft material Substances 0.000 claims abstract description 16
- 238000007873 sieving Methods 0.000 claims abstract description 6
- 238000005469 granulation Methods 0.000 claims abstract description 3
- 230000003179 granulation Effects 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 40
- 239000002245 particle Substances 0.000 claims description 29
- 210000004185 liver Anatomy 0.000 claims description 27
- 239000011812 mixed powder Substances 0.000 claims description 10
- 239000000843 powder Substances 0.000 claims description 10
- 230000036541 health Effects 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 239000012467 final product Substances 0.000 claims description 5
- 239000008213 purified water Substances 0.000 claims description 5
- 239000008188 pellet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 14
- 230000006870 function Effects 0.000 abstract description 12
- 239000002994 raw material Substances 0.000 abstract description 7
- 239000002552 dosage form Substances 0.000 abstract description 2
- 238000002156 mixing Methods 0.000 abstract 2
- 238000001035 drying Methods 0.000 abstract 1
- 231100000753 hepatic injury Toxicity 0.000 description 17
- 208000022309 Alcoholic Liver disease Diseases 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000463 material Substances 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 230000002443 hepatoprotective effect Effects 0.000 description 4
- 230000003859 lipid peroxidation Effects 0.000 description 4
- 208000019423 liver disease Diseases 0.000 description 4
- 238000003305 oral gavage Methods 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- 206010019728 Hepatitis alcoholic Diseases 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 208000002353 alcoholic hepatitis Diseases 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000035622 drinking Effects 0.000 description 3
- 235000021271 drinking Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 206010019692 hepatic necrosis Diseases 0.000 description 3
- 230000007866 hepatic necrosis Effects 0.000 description 3
- 210000003494 hepatocyte Anatomy 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 239000002932 luster Substances 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 206010036067 polydipsia Diseases 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- 210000000582 semen Anatomy 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 208000004930 Fatty Liver Diseases 0.000 description 2
- 206010019708 Hepatic steatosis Diseases 0.000 description 2
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 210000000013 bile duct Anatomy 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000000686 essence Substances 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000004584 weight gain Effects 0.000 description 2
- 235000019786 weight gain Nutrition 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- 208000007788 Acute Liver Failure Diseases 0.000 description 1
- 206010000804 Acute hepatic failure Diseases 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- XFXPMWWXUTWYJX-UHFFFAOYSA-N Cyanide Chemical compound N#[C-] XFXPMWWXUTWYJX-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 206010019668 Hepatic fibrosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 235000008331 Pinus X rigitaeda Nutrition 0.000 description 1
- 235000011613 Pinus brutia Nutrition 0.000 description 1
- 241000018646 Pinus brutia Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000003570 air Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 231100000359 cholestasis Toxicity 0.000 description 1
- 230000007870 cholestasis Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000010419 fine particle Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 210000000514 hepatopancreas Anatomy 0.000 description 1
- 230000003118 histopathologic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- ACFIXJIJDZMPPO-NCHANQSKSA-N nadph Chemical compound C1=CCC(C(=O)N)=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](COP(O)(=O)OP(O)(=O)OC[C@H]2[C@@H]([C@H](OP(O)(O)=O)[C@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 ACFIXJIJDZMPPO-NCHANQSKSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000575 pesticide Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000341 significant liver injury Toxicity 0.000 description 1
- 230000007863 steatosis Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- TXEYQDLBPFQVAA-UHFFFAOYSA-N tetrafluoromethane Chemical compound FC(F)(F)F TXEYQDLBPFQVAA-UHFFFAOYSA-N 0.000 description 1
- OBSZRRSYVTXPNB-UHFFFAOYSA-N tetraphosphorus Chemical compound P12P3P1P32 OBSZRRSYVTXPNB-UHFFFAOYSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 235000020795 whole food diet Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/13—Coniferophyta (gymnosperms)
- A61K36/15—Pinaceae (Pine family), e.g. pine or cedar
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/074—Ganoderma
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pollen pini and lucid ganoderma granule for protective chemical liver damage and belongs to the field of health-caring products. The health-caring product includes, by weight, 10-60 parts of pollen pini, 6-30 parts of a lucid ganoderma extract, and 10-60 parts of dextrin, wherein the mass ratio of the pollen pini, the lucid ganoderma extract to the dextrin is 2:1:2. The invention also relates to a preparation method of the pollen pini and lucid ganoderma granule. The preparation method includes the steps of: crushing and sieving the pollen pini, the lucid ganoderma extract and the dextrin, mixing the components, producing a soft material, performing granulation, and drying and finishing the granule. The pollen pini and lucid ganoderma extract are employed as raw materials, wherein the effects thereof are achieved greatest. The granule has simple raw material composition and is safe and pollution-free, and side effects due to blending of various raw materials are avoided. The product is in the dosage form of granule, which is low in dose and is convenient to take and carry. The granule includes fewer components, is low in cost, is convenient to take and has good effects and functions. The pollen pini and lucid ganoderma granule is safe and pollution-free and has protective effects on chemical liver damage.
Description
Technical field
The invention belongs to field of health care products, particularly to a kind of health product having defencive function to chemical liver, specifically
For a kind of Pollen Pini ganoderma particles of protection chemical liver and preparation method thereof.
Background technology
Liver is not only the maximum digestive gland of human body, is also the maximum metabolic organ of human body, it has digestion, absorption, generation
Thank, remove, detoxifying, hemopoietic, the several functions such as defecation, the toxin producing from external and body own metabolism is had powerful
Defence function of detoxification.
In daily life, Chemical Factors can be entered liver and be converted by gastrointestinal tract, blood circulation, therefore,
Liver is easily damaged by toxicant, causes chemical liver injury.Chemical liver injury refers to come from Working Life ring
Hepatic injury caused by the harmful chemical of border, food, medicine and a large amount of ethanol etc..These harmful chemical substances are included no
Machine poisonous substance (as heavy metal, cyanide, fluoride etc.), the chemical toxicant in food, drinking-water and air, pesticide, medicine, wine
Essence etc..
The mechanism of chemical toxicant liver injury mainly has: 1. steatosis.Carbon tetrachloride, yellow phosphorus etc. may interfere with lipoprotein
Synthesis and transhipment, form fatty liver.2. lipid peroxidation, this is the special representing form of toxic liver injury, such as tetrachloro
Change carbon and make body lipid Peroxidation Product malonaldehyde (mda) rising, Glutathione (gsh) and reduced coenzyme through internal metabolism
(nadph) reduce, lead to the lipid peroxidation on biomembrane, destroy the phospholipid of film, change structure and the function of cell.Such
Reaction most serious may result in hepatic necrosis.3. cholestasis reaction, is mainly manifested in acute liver damage, with liver plasma membrane and micro- floss
Impaired, the permeability changes of bile duct wall of hair, cause bile acid excretion obstacle, chemical substance deposits relevant in bile duct.
Alcoholic liver disease (alcoholic liver disease, ald) is modal chemical liver injury, is because of length
The hepatic injury that phase heavy drinking is led to.Initial stage is usually expressed as fatty liver, and then can develop into alcoholic hepatitis, hepatic fibrosis
And liver cirrhosis；Even a large amount of hepatic necrosis acute hepatic failures can be induced during serious excessive drinking.In recent years alcoholic liver disease morbidity and
Death condition is in increase trend rapidly in China.
National alcoholic liver disease investigation cooperative groups investigation display, China's alcoholic liver disease morbidity is in ascendant trend year by year.?
7 hospitals of Jilin, Hebei, Tianjin, Hubei etc. 7 provinces and cities are directed to 902 (men 893 that these hospitals are in hospital for 2000-2004 years
Example, female 9) patients with alcoholic liver disease case history, using " the alcoholic liver disease diagnosis guide " of the new revision of China, patient is drunk
The analysis that the extent of damage of amount, Time of drink, clinical symptoms, sickness rate and liver and other organ dysfunctions has carried out system is ground
Study carefully, and apply spss13.0 software to carry out statistical disposition to each item data.Result of study shows: China's patients with alcoholic liver disease drink
The wine time limit long, day the amount of drinking big.In 902 patients with alcoholic liver diseases, average Time of drink is 22.4, and average day takes in second
128.9 grams of alcohol amount, day drink amount be 640 grams to the maximum；The sickness rate of alcoholic liver disease be in year by year echelon rise, 2000,2001,
2002nd, in 2003,2004 years, other hepatopathy inpatient ratios that alcoholic liver disease sickness rate accounts for the same period in the same year are respectively
2.4%th, 2.7%, 2.8%, 3.4% and 4.3%；China's patients with alcoholic liver disease hepar damnification is serious, wherein alcoholic hepatitis
Patient accounts for 28.8%, and alcoholic cirrhosis patient accounts account for 37.4%.
In American-European countries, alcoholic liver disease is one of young and middle-aged main causes of death.According to estimates, the U.S. in 1993 there are about
15300000 people's excessive drinkings, have ten thousand people more than 200 with alcoholic liver patient；2.6 ten thousand people are had to die from liver cirrhosis, wherein at least 40% every year
Perhaps up to 90% patient has excessive drinking history.Have expert it is expected that from-the year two thousand fifty in 2005, Mexico will have more than 200 ten thousand chronic
Hepatopath, wherein Alcohol-Related hepatopathy is in the great majority, about 996255.The patient being in hospital because of hepatopathy in Portugal
In, alcoholic liver disease accounts for 63%, and the mortality rate of the simple alcoholic liver disease of more than 10 years is up to 60%.
Living environment deterioration, air pollution, heavy drinking etc. make the chemical liver injury such as alcoholic liver disease become occurred frequently
Disease, the life and health of the serious harm whole world people.Therefore, the health food of chemical liver injury defencive function is had wide
Development space.
Content of the invention
It is an object of the invention to provide a kind of material composition is few, low cost, preparation process is simple, taking convenience, effect
Function is good, safety non-pollution to chemical liver injury, there are Pollen Pini ganoderma particles of defencive function and preparation method thereof,
The object of the invention is achieved through the following technical solutions:
A kind of Pollen Pini ganoderma particles of protection chemical liver, described health product include the component of following mass parts: pine
10～60 parts of pollen, 6～30 parts of Ganoderma extract, 10～60 parts of dextrin, and the mass ratio of Pollen Pini, Ganoderma extract, dextrin
For 2:1:2.
A kind of preferred as the present invention, described health product include the component of following mass parts: Pollen Pini 15～40, Ganoderma
8～20 parts of extract, 15～40 parts of dextrin.
A kind of preferred as the present invention, described health product include the component of following mass parts: 18 parts of Pollen Pini, Ganoderma carries
Take 9 parts of thing, 18 parts of dextrin.
The invention still further relates to the preparation method of described Pollen Pini ganoderma particles, comprise the following steps:
1) sieve: Pollen Pini, Ganoderma extract, dextrin are pulverized and sieved, obtains fine powder standby；
2) mix: the Pollen Pini after sieving, Ganoderma extract, dextrin fine powder mix homogeneously obtain mixed powder；
3) soft material processed: mixed powder is mixed soft material processed with purified water；
4) pelletize: soft material is sieved, prepared wet granular；
5) it is dried: wet granular is dried, obtains dry particl；
6) granulate: dried pellet through sieves are carried out granulate, obtains final product Pollen Pini ganoderma particles of the present invention.
A kind of preferred as the present invention, in described sifting step, crossing grit number is 70-90 mesh；In described granulation step,
Crossing grit number is 12-18 mesh；In described granulate step, crossing grit number is 12-18 mesh.
A kind of preferred as the present invention, described baking temperature is 60～70 DEG C, and the time is 30～40min.
As a kind of preferred, the preparation method of described Pollen Pini ganoderma particles of the present invention, comprise the following steps:
1) sieve: Pollen Pini, Ganoderma extract, dextrin were pulverized 80 mesh sieves, obtains fine powder standby；
2) mix: the Pollen Pini after sieving, Ganoderma extract, dextrin fine powder mix homogeneously obtain mixed powder；
3) soft material processed: mixed powder is mixed soft material processed with purified water；
4) pelletize: soft material is crossed 16 mesh sieves, prepared wet granular；
5) it is dried: wet granular is dried 35min at a temperature of 65 DEG C, obtains dry particl；
6) granulate: dried granule is crossed 16 mesh sieves and carries out granulate, obtain final product Pollen Pini ganoderma particles of the present invention.
Pollen Pini has liver protection function, hepatocyte can be promoted to activate, make bile normal secretions, prevents sending out of hepatopathy
Raw, promote liver detoxification function；The lipid peroxidation injury to liver for the ethanol can be mitigated, strengthen fatty acid generation in hepatocyte
Thank, reduce fat and deposit in hepatocyte, the alcoholic cirrhosises being led to by excessive consumption of alcohol can be prevented.Ganoderma has liver protection
Detoxication, can prevent alcoholic hepatitis, the hepatic injury caused by protection carbon tetrachloride etc., mitigate hepatic injury degree etc..Dextrin master
The effect of binding agent to be played, formula material is bonded together and makes graininess, is convenient for carrying and takes, and improves the crowd of being suitable for
Acceptable sense.
It is primary raw material that this product selects Pollen Pini, Ganoderma extract, makes two kinds of composition phase interworkings with hepatoprotective
Close, realize a kind of individually inaccessiable effect of composition institute, realize complementary effect.Material composition of the present invention is simple, no
Unnecessary composition adds, and can at utmost ensure that the safe green of finished product is pollution-free, farthest avoids plurality of raw materials composition
Mix led to drug side effect.The each formulation content of the present invention is all to get through a large amount of scientific experimentss institutes, according to this
Invent allocation and content carries out the preparation of Pollen Pini ganoderma particles, can farthest play Pollen Pini and Ganoderma hepatoprotective
Effect, reach the effect got twice the result with half the effort.
Beneficial effects of the present invention:
1st, the present invention selects the most comprehensive Pollen Pini of nutritional labeling and traditional rare Chinese medicine Ganoderma extract in wholefood
For raw material, it is capable of a kind of inaccessiable effect of individually composition institute, improves the effect of hepatoprotective.
2nd, material composition of the present invention is simple, and no unnecessary composition adds, and can at utmost ensure the safe green of finished product no
Pollution, farthest avoids plurality of raw materials composition to mix led to drug side effect.
3rd, each formulation content of the present invention is all to get through a large amount of scientific experimentss institutes, allots and content according to the present invention
Carry out the preparation of Pollen Pini ganoderma particles, can farthest play effect of Pollen Pini and Ganoderma hepatoprotective, reach thing
The effect of half work(times.
4th, this product select granule as dosage form, dosage is little, take, carry, preserving, transport more convenient, improve be suitable for
The acceptable sense of crowd.
Brief description
Fig. 1 is the preparation technology flow chart of Pollen Pini ganoderma particles of the present invention.
Specific embodiment
In order that the objects, technical solutions and advantages of the present invention become more apparent, below in conjunction with drawings and Examples, right
The present invention is further elaborated.It should be appreciated that specific embodiment described herein is only in order to explain the present invention, and
It is not used in the restriction present invention.
The preparation of embodiment 1 Pollen Pini ganoderma particles product
The formula components of Pollen Pini ganoderma particles and content are as shown in table 1 below:
The formula components of table 1 Pollen Pini ganoderma particles and content
The concrete preparation process of product 1 is as follows:
1) sieve: Pollen Pini, Ganoderma extract, dextrin were pulverized 80 mesh sieves, obtains fine powder standby；
2) mix: the Pollen Pini after sieving, Ganoderma extract, dextrin fine powder mix homogeneously obtain mixed powder；
3) soft material processed: mixed powder is mixed soft material processed with purified water；
4) pelletize: soft material is crossed 16 mesh sieves, prepared wet granular；
5) it is dried: wet granular is dried 35min at a temperature of 65 DEG C, obtains dry particl；
6) granulate: dried granule is crossed 16 mesh sieves and carries out granulate, obtain final product Pollen Pini ganoderma particles product of the present invention.
Product is packed as 1000 bags, every bag of 4.5g.
The preparation technology of product 2～product 4 is identical with product 1.
Embodiment 2 Pollen Pini ganoderma particles product functionality effect experimental
1. materials and methods
1.1 samples:
Pollen Pini ganoderma particles product 1～4, is assigned to desired concn for experiment with distilled water after crushed.
1.2 laboratory animals:
The cleaning grade jcr healthy male mice 60 that Shanghai Slac Experimental Animal Co., Ltd. provides, body weight 18-20g,
Animal is randomly divided into 5 groups by body weight, every group 12.
1.3 dosage choice
Product 1～4 people's recommended amounts are 4.5g/d, i.e. 0.075g/kg bw (adult's body weight is in terms of 60kg), by people's recommended amounts
30 times set dosage group as 2.25g/kg bw, that is, press 112.5mg/ml concentration prepare, separately set solvent control group (distilled water) and
ccl4Model control group.ccl4Solvent select Semen Maydis oil, ccl4Dosage is 26mg/kg bw.
1.4 feeding environment
Disease Control and Prevention Center of Fujian Province spf level Animal Lab.,
1.5 experiment things give to count:
Animal presses the oral gavage of 0.02ml/g body weight daily, continuous 30 days.
1.6 key instruments and reagent
Hitachi 7060 automatic clinical chemistry analyzer；Automatic water extracter for biological tissue, biological tissue's frozen embedding machine；
Finesse325 paraffin slicing machine；Full-automatic dyeing machine；Bx-51 microscope；Biochemical reagents box is purchased from the biochemical examination of Beijing Li Deman
Agent company limited, analyzes pure carbon tetrafluoride (ccl4) it is purchased from Shanghai Changjiang River chemical plant, being configured to concentration with Semen Maydis oil is 2.6mg/
ml.
1.7 experimental data statistical method
Experimental data is counted with spss software, solvent control group and ccl4Model control group compares with t inspection, various kinds
Product group and ccl4Model control group compares uses one factor analysis of variance.Through homogeneity of variance experiment, the neat experimental data of variance adopts
Lsd method carries out statistical analysiss, heterogeneity of variance or nonnormal experimental data is first carried out with variable conversion and counts.
1.8 experimental technique
Animal per day, oral gavage gave tested material, and solvent control group and model control group give distilled water.Animal is weekly
Weigh twice, to adjust tested material dosage, free diet drinking-water.In experiment the 30th day by fasting overnight for each group animal 16 hours,
Model group and product group animal give the ccl of 2.6mg/ml by gavage of 0.01ml/g bw4Contamination, solvent control group gives
Semen Maydis oil, each tested group through ccl4Contamination continued to give given the test agent after 4 hours, gave ccl4Pluck eyeball after 24 hours and take blood,
Separate serum, measure alt, ast, put to death animal simultaneously, go liver to carry out histopathological examination.
2. result
The impact of 1.2 1～4 pair of Mouse Weight of product
The original body mass of product 1～4 mice, terminate weight gain and the results are shown in Table 2:
The original body mass of table 2 mice, terminate body weight, weightening (g)
From table 2 it can be seen that the original body mass Analysis of variance of product 1～4 each group mice, no significant difference (p
> 0.05), that is, the original body mass of mice more equalizes between each group, and oral gavage is after 30 days, the weight gain value warp of each group mice
Variance analyses, no significant difference (p > 0.05), that is, product 1～4 no affects on the body weight increase of mice.
The impact of 2.2 product 1～4 couple of serum alt, ast
The impact of product 1～4 couple of mice serum alt, ast the results are shown in Table 3:
The assay of table 3 mice alt, ast
*With ccl4Model control group compares, p < 0.05
From table 3 it can be seen that during off-test, ccl4Alt, ast value of model control group mice is higher than solvent control group,
Through statistical discrepancy statistically significant (p ＜ 0.05), alt, ast value of product 1～4 is below ccl4 model control group, and with
Model control group compares, difference statistically significant (p ＜ 0.05).Illustrate that product 1～4 can significantly inhibit ccl4Blood after hepatic injury
The rising of clear alt, ast value, has significant liver injury protection effect.
2.3 pathology of hepar inspection results
2.3.1 perusal
Solvent control group: liver surface flat smooth, color and luster bright in cerise, matter soft.
ccl4Model control group: liver surface has graininess, color and luster thin out in khaki, matter is slightly hard.
1～4 group of product: liver surface has uniform fine particles, color and luster is in slightly yellow, dark brown or khaki, and matter is soft or slightly hard:
2.3.2 microscopy
Table 4 product 1～4 mouse liver histopathologic examination result (integration)
Numerical value in () is and ccl4The p value that model control group compares.
As shown in Table 4, ccl4Model control group hepatic injury degree is higher than solvent control group, the hepatic necrosis of product 1～4
Integration and total mark are less than ccl4Model control group, and through statistical analysis, have significant difference (p < 0.5), illustrate product 1～
The degree of injury of 4 pairs of livers is substantially less than ccl4Model control group, has defencive function effect to chemical liver injury.
3. experiment conclusion
Pollen Pini ganoderma particles of the present invention increase to Mouse Weight and growth has no adverse effects, and oral gavage gives mice originally
After invention product 1～4 30 days, Pollen Pini ganoderma particles product of the present invention can significantly inhibit the 24th hour blood after ccl4 hepatic injury
The rising of clear alt, ast value, liver case inspection result shows: 1～4 group of hepar damnification degree of product is substantially less than ccl4Model
Matched group, shows that Pollen Pini ganoderma particles of the present invention have significant assistant protection function to chemical liver injury.
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all essences in the present invention
Any modification, equivalent and improvement made within god and principle etc., should be included within the scope of the present invention.
Claims (7)
1. a kind of Pollen Pini ganoderma particles of protection chemical liver are it is characterised in that described health product include following mass parts
Component: 10～60 parts of Pollen Pini, 6～30 parts of Ganoderma extract, 10～60 parts of dextrin, and Pollen Pini, Ganoderma extract, dextrin
Mass ratio be 2:1:2.
2. as claimed in claim 1 a kind of Pollen Pini ganoderma particles of protection chemical liver it is characterised in that described health product
Component including following mass parts: 8～20 parts of Pollen Pini 15～40, Ganoderma extract, 15～40 parts of dextrin.
3. as claimed in claim 1 a kind of Pollen Pini ganoderma particles of protection chemical liver it is characterised in that described health product
Component including following mass parts: 18 parts of Pollen Pini, 9 parts of Ganoderma extract, 18 parts of dextrin.
4. as claimed in claim 1 a kind of protection chemical liver Pollen Pini ganoderma particles preparation method it is characterised in that
Comprise the following steps:
1) sieve: Pollen Pini, Ganoderma extract, dextrin are pulverized and sieved, obtains fine powder standby；
2) mix: the Pollen Pini after sieving, Ganoderma extract, dextrin fine powder mix homogeneously obtain mixed powder；
3) soft material processed: mixed powder is mixed soft material processed with purified water；
4) pelletize: soft material is sieved, prepared wet granular；
5) it is dried: wet granular is dried, obtains dry particl；
6) granulate: dried pellet through sieves are carried out granulate, obtains final product Pollen Pini ganoderma particles of the present invention.
5. as claimed in claim 4 a kind of protection chemical liver Pollen Pini ganoderma particles preparation method it is characterised in that
In described sifting step, crossing grit number is 70-90 mesh；In described granulation step, crossing grit number is 12-18 mesh；Described granulate step
In rapid, crossing grit number is 12-18 mesh.
6. as claimed in claim 4 a kind of protection chemical liver Pollen Pini ganoderma particles preparation method it is characterised in that
Described baking temperature is 60～70 DEG C, and the time is 30～40min.
7. as claimed in claim 4 a kind of protection chemical liver Pollen Pini ganoderma particles preparation method it is characterised in that
Comprise the following steps:
1) sieve: Pollen Pini, Ganoderma extract, dextrin were pulverized 80 mesh sieves, obtains fine powder standby；
2) mix: the Pollen Pini after sieving, Ganoderma extract, dextrin fine powder mix homogeneously obtain mixed powder；
3) soft material processed: mixed powder is mixed soft material processed with purified water；
4) pelletize: soft material is crossed 16 mesh sieves, prepared wet granular；
5) it is dried: wet granular is dried 35min at a temperature of 65 DEG C, obtains dry particl；
6) granulate: dried granule is crossed 16 mesh sieves and carries out granulate, obtain final product Pollen Pini ganoderma particles of the present invention.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610729498.4A CN106360708A (en) | 2016-08-26 | 2016-08-26 | Pollen pini and lucid ganoderma granule for protective chemical liver damage and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610729498.4A CN106360708A (en) | 2016-08-26 | 2016-08-26 | Pollen pini and lucid ganoderma granule for protective chemical liver damage and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106360708A true CN106360708A (en) | 2017-02-01 |
Family
ID=57902600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610729498.4A Pending CN106360708A (en) | 2016-08-26 | 2016-08-26 | Pollen pini and lucid ganoderma granule for protective chemical liver damage and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106360708A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019644A (en) * | 2007-03-10 | 2007-08-22 | 溧阳市天目湖保健品有限公司 | Health food with auxiliary function of protecting liver against chemical damage and its prepn |
| CN102988429A (en) * | 2013-01-10 | 2013-03-27 | 三门峡山水方正生物科技有限公司 | Pine pollen tablet for preventing alcoholic liver damages |
-
2016
- 2016-08-26 CN CN201610729498.4A patent/CN106360708A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101019644A (en) * | 2007-03-10 | 2007-08-22 | 溧阳市天目湖保健品有限公司 | Health food with auxiliary function of protecting liver against chemical damage and its prepn |
| CN102988429A (en) * | 2013-01-10 | 2013-03-27 | 三门峡山水方正生物科技有限公司 | Pine pollen tablet for preventing alcoholic liver damages |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ogbonnia et al. | Antimicrobial evaluation, acute and subchronic toxicity studies of Leone Bitters, a Nigerian polyherbal formulation, in rodents | |
| Tumir et al. | Monitoring of metal and metalloid content in dietary supplements on the Croatian market | |
| Nguyen et al. | Growth and feed utilisation of Nile tilapia (Oreochromis niloticus) fed different protein levels in a clear-water or biofloc-RAS system | |
| CN108576819A (en) | A kind of liver-protecting combination, health food, preparation method and applications | |
| Abdelhiee et al. | The impact of Moringa oleifera on the health status of Nile tilapia exposed to aflatoxicosis | |
| Gültepe et al. | Effects of dietary Tribulus terrestris extract supplementation on growth, feed utilization, hematological, immunological, and biochemical variables of Nile tilapia Oreochromis niloticus | |
| Oladiji et al. | Anti-anaemic potentials of aqueous extract of Sorghum bicolor (L.) moench stem bark in rats | |
| Sun et al. | Effects of dietary dandelion extracts on growth performance, liver histology, immune-related gene expression and CCl4 resistance of hybrid grouper (Epinephelus lanceolatus♂× Epinephelus fuscoguttatus♀) | |
| CN103564197A (en) | Compound plant extract feed additive and preparation method thereof | |
| CN106214773B (en) | A kind of pair of chemical damage has composition of assistant protection function and preparation method thereof | |
| Peng et al. | Effect of diets supplemented with different sources of astaxanthin on the gonad of the sea urchin Anthocidaris crassispina | |
| CN104644694A (en) | Preparation method of ultramicro spirulina powder as well as preparation and application thereof | |
| Harikrishnan et al. | Immune defense of emodin enriched diet in Clarias batrachus against Aeromonas hydrophila | |
| Khan et al. | Comprehensive nutrients analysis of rhizomes of Polygonatum verticillatum. | |
| CN106362020B (en) | A kind of pine pollen composition and preparation method thereof with improvement defecating feces excretion | |
| CN103142765A (en) | Total nutrient ganoderma lucidum snake wine containing rich selenium germanium nano elements and vitamins | |
| Ajuru et al. | Proximate and phytochemical analysis of the leaves of Justicia carnea Lindi. and Justicia secunda Vahl and its taxonomic implications | |
| Pulido-Hornedo et al. | Hepatoprotective effect of Opuntia robusta fruit biocomponents in a rat model of thioacetamide-induced liver fibrosis | |
| CN102188486B (en) | Pharmaceutical composition for preventing and treating fatty liver and preparation method thereof | |
| CN102106895B (en) | Composition with function of regulating blood fat | |
| CN103127395B (en) | Dendrobe anti-oxidation preparation and preparation method thereof | |
| CN106360708A (en) | Pollen pini and lucid ganoderma granule for protective chemical liver damage and preparation method thereof | |
| CN104383447A (en) | Traditional Chinese medicine composition as well as preparation method and application thereof | |
| CN106376919A (en) | Pine pollen and ganoderma lucidum capsule for protecting people from chemical liver injury, and preparation method thereof | |
| Saari et al. | Effects of Canarium odontophyllum leaves on plasma glucose and T lymphocyte population in streptozotocin-induced diabetic rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170201 |
|
| RJ01 | Rejection of invention patent application after publication |